CGEMCullinan Therapeutics, Inc.
What is the market doing?
No clear lean: nothing decisive, though a crowded short (+16% of shares).
Choppy, but holding above its 200-day average. Oversold (RSI 24). Price is +3% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
A crowded short, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How CGEM is trading
Cullinan Therapeutics, Inc. is +150% over the past year while the S&P 500 is +18%: 132 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +3.3%
vs 200-day average · close to trend
- RSI (14)
- 24
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 32%
Below its 52-week high
Details›
- Last close2026-10-09
- $15.53
- 1 monthS&P 500 +2.7%
- −26%
- 1 yearS&P 500 +18%
- +150%
- 5 yearsS&P 500 +88%
- −46%
- vs 50-day average$19.19
- −19%
- 52-week high
- $22.98
- 52-week low
- $5.75
- Annualised volatility
- 71%
| Year | Return |
|---|---|
| 2026 (year to date) | +50% |
| 2025 | −15% |
| 2024 | +20% |
| 2023 | −3.4% |
| 2022 | −32% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 5 | 3 of 5 | +9.7% |
| Feb | 6 | 4 of 6 | +7.0% |
| Mar | 6 | 1 of 6 | −10% |
| Apr | 6 | 2 of 6 | +4.4% |
| May | 6 | 4 of 6 | +3.9% |
| Jun | 6 | 3 of 6 | −2.5% |
| Jul | 6 | 3 of 6 | +0.26% |
| Aug | 6 | 3 of 6 | +7.5% |
| Sep | 6 | 0 of 6 | −17% |
| Oct | 6 | 4 of 6 | +7.4% |
| Nov | 5 | 1 of 5 | −3.8% |
| Dec | 5 | 1 of 5 | −4.7% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.